Abstract
Malignant tumors of the digestive system, with high morbidity and mortality rate, are insidious at the onset and lack of effective treatments so far. Interleukin-22 (IL-22) is one of the members of the IL-10 cytokine family discovered in recent years and was originally called IL-10-associated T cell differentiation inducing factor (IL-TIF). IL-22 expression is elevated in various digestive system malignant tumors, and increased IL-22 expression is associated with tumor progression and poor prognosis. Studies on the molecular mechanism revealed that IL-22 initiates a series of downstream signaling pathways such as JAK/STAT and MAPK, by acting on the IL-22 receptor, inducing tumorigenesis. IL-22 is expected to be a novel diagnostic biomarker and therapeutic target of digestive system malignant tumor.(Chin J Lab Med, 2018, 41: 720-723) Key words: Digestive system neoplasms; Interleukins; Biomarkers, tumor
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
